Lindsey Trickett
Investor Relations Contact chez F-STAR THERAPEUTICS, INC.
Postes actifs de Lindsey Trickett
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| F-STAR THERAPEUTICS, INC. | Investor Relations Contact | - | - |
| Public Communications Contact | - | - | |
| PRELUDE THERAPEUTICS INCORPORATED | Investor Relations Contact | - | - |
Historique de carrière de Lindsey Trickett
Anciens postes connus de Lindsey Trickett
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INTELLIA THERAPEUTICS, INC. | Investor Relations Contact | 07/09/2017 | - |
Formation de Lindsey Trickett
| University of Kentucky | Undergraduate Degree |
| Georgetown University | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 5 |
| Royaume-Uni | 2 |
Opérationnelle
| Investor Relations Contact | 3 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| Entreprise privées | 1 |
|---|---|
F-star Therapeutics, Inc.
 F-star Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Lindsey Trickett
- Expérience